EMA Authorised: Vimizim (recombinant human n-acetylgalactosamine-6-sulfatase) — BioMarin International Limited

View source ↗

Summary

The European Medicines Agency authorised Vimizim for the treatment of Mucopolysaccharidosis IVA (Morquio A) in 2021; Vimizim is an enzyme replacement therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Iva

Drugs mentioned

• VIMIZIM (Elosulfase alfa)

Snippet

Status: Authorised. Therapeutic area: Mucopolysaccharidosis IV. MAH: BioMarin International Limited. Decision date: 09/04/2021